Differential Engagement by Race/Ethnicity in Experimental Trials of Mental Health Treatment Interventions: A Systematic Review

References (142)

1. Maura J, Weisman de Mamani A. Mental health disparities, treatment engagement, and attrition among racial/ethnic minorities with severe mental illness: A review. J Clin Psychol Med Settings. 2017;24(3-4):187–210. PubMed CrossRef
2. Olfson M, Cherry DK, Lewis-Fernández R. Racial differences in visit duration of outpatient psychiatric visits. Arch Gen Psychiatry. 2009;66(2):214–221. PubMed CrossRef
3. Cook JM, Thompson R, Harb GC, et al. Cognitive-behavioral treatment for posttraumatic nightmares: an investigation of predictors of dropout and outcome. Psychol Trauma. 2013;5(6):545–553. CrossRef
4. Harman JS, Edlund MJ, Fortney JC. Disparities in the adequacy of depression treatment in the United States. Psychiatr Serv. 2004;55(12):1379–1385. PubMed CrossRef
5. Lanouette NM, Folsom DP, Sciolla A, et al. Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review. Psychiatr Serv. 2009;60(2):157–174. PubMed CrossRef
6. Lewis-Fernández R, Coombs AA, Balán IC, et al. Motivational interviewing: overcoming disparities in pharmacotherapy engagement. J Clin Psychiatry. 2018;79(3):18ac12150. PubMed CrossRef
7. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101–108. PubMed CrossRef
8. Chen J, Rizzo JA. Racial and ethnic disparities in antidepressant drug use. J Ment Health Policy Econ. 2008;11(4):155–165. PubMed
9. Kreyenbuhl J, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophr Bull. 2009;35(4):696–703. PubMed CrossRef
10. O’Brien A, Fahmy R, Singh SP. Disengagement from mental health services: a literature review. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):558–568. PubMed CrossRef
11. Alegría M, Alvarez K, Ishikawa RZ, et al. Removing obstacles to eliminating racial and ethnic disparities in behavioral health care. Health Aff (Millwood). 2016;35(6):991–999. PubMed CrossRef
12. Dixon LB, Holoshitz Y, Nossel I. Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry. 2016;15(1):13–20. PubMed CrossRef
13. Woodall A, Morgan C, Sloan C, et al. Barriers to participation in mental health research: are there specific gender, ethnicity and age related barriers? BMC Psychiatry. 2010;10(1):103. PubMed CrossRef
14. Fleming MD, Shim JK, Yen IH, et al. Patient engagement at the margins: Health care providers’ assessments of engagement and the structural determinants of health in the safety-net. Soc Sci Med. 2017;183:11–18. PubMed CrossRef
15. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805–811. PubMed CrossRef
16. McGuire TG, Miranda J. New evidence regarding racial and ethnic disparities in mental health: policy implications. Health Aff (Millwood). 2008;27(2):393–403. PubMed CrossRef
17. Aggarwal NK, Pieh MC, Dixon L, et al. Clinician descriptions of communication strategies to improve treatment engagement by racial/ethnic minorities in mental health services: a systematic review. Patient Educ Couns. 2016;99(2):198–209. PubMed CrossRef
18. Smedley BD, Stith AY, Nelson AR. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
19. Office of the Surgeon General (US), Center for Mental Health Services (US), National Institute of Mental Health (US). Mental Health: Culture, Race, and Ethnicity: A Supplement to Mental health: A Report of the Surgeon General. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001.
20. Borowsky SJ, Rubenstein LV, Meredith LS, et al. Who is at risk of nondetection of mental health problems in primary care? J Gen Intern Med. 2000;15(6):381–388. PubMed CrossRef
21. Snowden LR. Bias in mental health assessment and intervention: theory and evidence. Am J Public Health. 2003;93(2):239–243. PubMed CrossRef
22. Jimenez DE, Bartels SJ, Cardenas V, et al. Cultural beliefs and mental health treatment preferences of ethnically diverse older adult consumers in primary care. Am J Geriatr Psychiatry. 2012;20(6):533–542. PubMed CrossRef
23. Williamson LD, Smith MA, Bigman CA. Does discrimination breed mistrust? examining the role of mediated and non-mediated discrimination experiences in medical mistrust. J Health Commun. 2019;24(10):791–799. PubMed CrossRef
24. Durant RW, Legedza AT, Marcantonio ER, et al. Different types of distrust in clinical research among whites and African Americans. J Natl Med Assoc. 2011;103(2):123–130. PubMed CrossRef
25. Abdullah T, Brown TL. Mental illness stigma and ethnocultural beliefs, values, and norms: an integrative review. Clin Psychol Rev. 2011;31(6):934–948. PubMed CrossRef
26. Vargas SM, John RS, Garro LC, et al. Measuring congruence in problem definition of Latino patients and their psychotherapists: an exploratory study. Hisp J Behav Sci. 2019;41(3):392–411. CrossRef
27. Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health. 2015;105(12):e60–e76. PubMed CrossRef
28. Bauer AM, Alegría M. Impact of patient language proficiency and interpreter service use on the quality of psychiatric care: a systematic review. Psychiatr Serv. 2010;61(8):765–773. PubMed CrossRef
29. Lillie-Blanton M, Hoffman C. The role of health insurance coverage in reducing racial/ethnic disparities in health care. Health Aff (Millwood). 2005;24(2):398–408. PubMed CrossRef
30. George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health. 2014;104(2):e16–e31. PubMed CrossRef
31. DeRigne L, Stoddard-Dare P, Quinn L. Workers without paid sick leave less likely to take time off for illness or injury compared to those with paid sick leave. Health Aff (Millwood). 2016;35(3):520–527. PubMed CrossRef
32. Doyle R, Turner N, Fanning F, et al. First-episode psychosis and disengagement from treatment: a systematic review. Psychiatr Serv. 2014;65(5):603–611. PubMed CrossRef
33. Reynolds S, Kim DJ, Brown E, et al. Defining disengagement from mental health services for individuals experiencing first episode psychosis: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2019;54(11):1325–1335. PubMed CrossRef
34. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372(160):n160. PubMed CrossRef
35. Office of Management and Budget (OMB) Standards. Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. Govinfo website.https://www.govinfo.gov/content/pkg/FR-1997-10-30/pdf/97-28653.pdf. Accessed April 19, 2021.
36. Higgins JPT, Green S. Higgins JPT, et al. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration website. https://training.cochrane.org/handbook/archive/v5.1/. Updated March 2011.
37. Aharonovich E, Hasin DS, Brooks AC, et al. Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend. 2006;81(3):313–322. PubMed CrossRef
38. Gonzalez Arnold J, Salcedo S, Ketter TA, et al. An exploratory study of responses to low-dose lithium in African Americans and Hispanics. J Affect Disord. 2015;178:224–228. PubMed CrossRef
39. Arnow BA, Blasey C, Manber R, et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord. 2007;97(1-3):197–202. PubMed CrossRef
40. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462–1470. PubMed CrossRef
41. Blanco C, Markowitz JC, Hellerstein DJ, et al. A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer. Breast Cancer Res Treat. 2019;173(2):353–364. PubMed CrossRef
42. Blow FC, Walton MA, Murray R, et al. Intervention attendance among emergency department patients with alcohol- and drug-use disorders. J Stud Alcohol Drugs. 2010;71(5):713–719. PubMed CrossRef
43. Bogner HR, Lin JY, Morales KH. Patterns of early adherence to the antidepressant citalopram among older primary care patients: the prospect study. Int J Psychiatry Med. 2006;36(1):103–119. PubMed CrossRef
44. Brown ES, Tirado C, Minhajuddin A, et al. Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy. J Ethn Subst Abuse. 2010;9(2):106–114. PubMed CrossRef
45. Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104(2):256–265. PubMed CrossRef
46. Cheng P, Luik AI, Fellman-Couture C, et al. Efficacy of digital CBT for insomnia to reduce depression across demographic groups: a randomized trial. Psychol Med. 2019;49(3):491–500. PubMed CrossRef
47. Cook JM, Harb GC, Gehrman PR, et al. Imagery rehearsal for posttraumatic nightmares: a randomized controlled trial. J Trauma Stress. 2010;23(5):553–563. PubMed CrossRef
48. Dansereau DF, Joe GW, Dees SM, et al. Ethnicity and the effects of mapping-enhanced drug abuse counseling. Addict Behav. 1996;21(3):363–376. PubMed CrossRef
49. Joe GW, Dansereau DF, Simpson DD. Node-link mapping for counseling cocaine users in methadone treatment. J Subst Abuse. 1994;6(4):393–406. PubMed CrossRef
50. Falkenstein MJ, Rogers K, Malloy EJ, et al. Race/ethnicity and treatment outcome in a randomized controlled trial for trichotillomania (hair-pulling disorder). J Clin Psychol. 2015;71(7):641–652. PubMed CrossRef
51. Rogers K, Banis M, Falkenstein MJ, et al. Stepped care in the treatment of trichotillomania. J Consult Clin Psychol. 2014;82(2):361–367. PubMed CrossRef
52. Hasin DS, Aharonovich E, Greenstein E. HealthCall for the smartphone: technology enhancement of brief intervention in HIV alcohol dependent patients. Addict Sci Clin Pract. 2014;9(1):5. PubMed CrossRef
53. Hoblyn JC, Rosenheck RA, Leatherman S, et al; CSP 555 Investigator Group. Veteran subjects willingness to participate in schizophrenia clinical trials. Psychiatr Q. 2013;84(2):209–218. PubMed CrossRef
54. Rosenheck RA, Leslie DL, Sindelar J, et al; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080–2089. PubMed CrossRef
55. Horvitz-Lennon M, Zhou D, Normand SL, et al. Racial and ethnic service use disparities among homeless adults with severe mental illnesses receiving ACT. Psychiatr Serv. 2011;62(6):598–604. PubMed CrossRef
56. Randolph F, Blasinsky M, Morrissey JP, et al; ACCESS National Evaluation Team; Access to Community Care and Effective Services and Supports. Overview of the ACCESS Program. Psychiatr Serv. 2002;53(8):945–948. PubMed CrossRef
57. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87. PubMed CrossRef
58. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1-2):71–76. PubMed CrossRef
59. Jarrett RB, Minhajuddin A, Kangas JL, et al. Acute phase cognitive therapy for recurrent major depressive disorder: who drops out and how much do patient skills influence response? Behav Res Ther. 2013;51(4-5):221–230. PubMed CrossRef
60. Jarrett RB, Thase ME. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up. Contemp Clin Trials. 2010;31(4):355–377. PubMed CrossRef
61. Johnson S, Price M, Mehta N, et al. Stereotype confirmation concerns predict dropout from cognitive behavioral therapy for social anxiety disorder. BMC Psychiatry. 2014;14(1):233. PubMed CrossRef
62. Anderson PL, Price M, Edwards SM, et al. Virtual reality exposure therapy for social anxiety disorder: a randomized controlled trial. J Consult Clin Psychol. 2013;81(5):751–760. PubMed CrossRef
63. Kalapatapu RK, Ho J, Cai X, et al. Cognitive-behavioral therapy in depressed primary care patients with co-occurring problematic alcohol use: effect of telephone-administered vs face-to-face treatment-a secondary analysis. J Psychoactive Drugs. 2014;46(2):85–92. PubMed CrossRef
64. Mohr DC, Ho J, Duffecy J, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. JAMA. 2012;307(21):2278–2285. PubMed CrossRef
65. Keefe JR, Wiltsey Stirman S, Cohen ZD, et al. In rape trauma PTSD, patient characteristics indicate which trauma-focused treatment they are most likely to complete. Depress Anxiety. 2018;35(4):330–338. PubMed CrossRef
66. Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002;70(4):867–879. PubMed CrossRef
67. Kelly SM, O’Grady KE, Mitchell SG, et al. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011;117(2-3):170–175. PubMed CrossRef
68. Kleinman PH, Kang SY, Lipton DS, et al. Retention of cocaine abusers in outpatient psychotherapy. Am J Drug Alcohol Abuse. 1992;18(1):29–43. PubMed CrossRef
69. Kurtz MM, Rose J, Wexler BE. Predictors of participation in community outpatient psychosocial rehabilitation in schizophrenia. Community Ment Health J. 2011;47(6):622–627. PubMed CrossRef
70. Kurtz MM, Seltzer JC, Shagan DS, et al. Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient? Schizophr Res. 2007;89(1–3):251–260. PubMed CrossRef
71. Lee CS, Liebschutz JM, Anderson BJ, et al. Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge. Am J Addict. 2017;26(7):667–672. PubMed CrossRef
72. Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376. PubMed CrossRef
73. Lesser IM, Zisook S, Gaynes BN, et al. Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. Psychiatr Serv. 2011;62(10):1167–1179. PubMed CrossRef
74. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689–701. PubMed CrossRef
75. Lester K, Resick PA, Young-Xu Y, et al. Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. J Consult Clin Psychol. 2010;78(4):480–489. PubMed CrossRef
76. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007;87(1):20–29. PubMed CrossRef
77. McCarthy DE, Versella MV. Quitting failure and success with and without using medication: latent classes of abstinence and adherence to nicotine monotherapy, combination therapy, and varenicline. Nicotine Tob Res. 2019;21(11):1488–1495. PubMed CrossRef
78. Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial. JAMA. 2016;315(4):371–379. PubMed CrossRef
79. Milligan CO, Nich C, Carroll KM. Ethnic differences in substance abuse treatment retention, compliance, and outcome from two clinical trials. Psychiatr Serv. 2004;55(2):167–173. PubMed CrossRef
80. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994;51(3):177–187. PubMed CrossRef
81. Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998;93(5):713–727. PubMed CrossRef
82. Miranda J, Azocar F, Organista KC, et al. Treatment of depression among impoverished primary care patients from ethnic minority groups. Psychiatr Serv. 2003;54(2):219–225. PubMed CrossRef
83. Montgomery L, Petry NM, Carroll KM. Moderating effects of race in clinical trial participation and outcomes among marijuana-dependent young adults. Drug Alcohol Depend. 2012;126(3):333–339. PubMed CrossRef
84. Carroll KM, Easton CJ, Nich C, et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol. 2006;74(5):955–966. PubMed CrossRef
85. Nwokeji ED, Bohman TM, Wallisch L, et al. Evaluating patient adherence to antidepressant therapy among uninsured working adults diagnosed with major depression: results of the Texas Demonstration to Maintain Independence and Employment study. Adm Policy Ment Health. 2012;39(5):374–382. PubMed CrossRef
86. Gimm G, Denny-Brown N, Gilman B, et al. Interim Report on the Demonstration to Maintain Independence and Employment. Mathematica website. https://www.mathematica.org/our-publications-and-findings/publications/interim-report-on-the-demonstration-to-maintain-independence-and-employment. April 2009. Accessed January 23, 2020.
87. Rosenblum A, Fallon B, Magura S, et al. The autonomy of mood disorders among cocaine-using methadone patients. Am J Drug Alcohol Abuse. 1999;25(1):67–80. PubMed CrossRef
88. Magura S, Rosenblum A, Lovejoy M, et al. Neurobehavioral treatment for cocaine-using methadone patients: a preliminary report. J Addict Dis. 1994;13(4):143–160. PubMed CrossRef
89. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry. 2000;61(5):382–386. PubMed CrossRef
90. Ruglass LM, Hien DA, Hu MC, et al. Racial/ethnic match and treatment outcomes for women with PTSD and substance use disorders receiving community-based treatment. Community Ment Health J. 2014;50(7):811–822. PubMed CrossRef
91. Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol. 2009;77(4):607–619. PubMed CrossRef
92. Ruglass LM, Pedersen A, Cheref S, et al. Racial differences in adherence and response to combined treatment for full and subthreshold post-traumatic stress disorder and alcohol use disorders: a secondary analysis. J Ethn Subst Abuse. 2016;15(4):434–448. PubMed CrossRef
93. Hien DA, Levin FR, Ruglass L, et al. Enhancing the effects of cognitive behavioral therapy for PTSD and alcohol use disorders with antidepressant medication: a randomized clinical trial. Drug Alcohol Depend. 2015;146:e142. CrossRef
94. Saxon AJ, Wells EA, Fleming C, et al. Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction. 1996;91(8):1197–1210. PubMed CrossRef
95. Siqueland L, Crits-Christoph P, Frank A, et al. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend. 1998;52(1):1–13. PubMed CrossRef
96. Siqueland L, Crits-Christoph P, Gallop B, et al. Who starts treatment: engagement in the NIDA collaborative cocaine treatment study. Am J Addict. 2002;11(1):10–23. PubMed CrossRef
97. Crits-Christoph P, Siqueland L, Blaine J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry. 1999;56(6):493–502. PubMed CrossRef
98. Siqueland L, Crits-Christoph P, Gallop R, et al. Retention in psychosocial treatment of cocaine dependence: predictors and impact on outcome. Am J Addict. 2002;11(1):24–40. PubMed CrossRef
99. Stein MD, Herman DS, Kettavong M, et al. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010;39(2):157–166. PubMed CrossRef
100. Sullivan MA, Bisaga A, Pavlicova M, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176(2):129–137. PubMed CrossRef
101. Svikis DS, Lee JH, Haug NA, et al. Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend. 1997;48(1):33–41. PubMed CrossRef
102. Jansson LM, Svikis D, Lee J, et al. Pregnancy and addiction: a comprehensive care model. J Subst Abuse Treat. 1996;13(4):321–329. PubMed CrossRef
103. Tate SR, Mrnak-Meyer J, Shriver CL, et al. Predictors of treatment retention for substance-dependent adults with co-occurring depression. Am J Addict. 2011;20(4):357–365. PubMed CrossRef
104. Thompson-Brenner H, Franko DL, Thompson DR, et al. Race/ethnicity, education, and treatment parameters as moderators and predictors of outcome in binge eating disorder. J Consult Clin Psychol. 2013;81(4):710–721. PubMed CrossRef
105. Vendetti J, McRee B, Miller M, et al; Marijuana Treatment Project Research Group. Correlates of pre-treatment drop-out among persons with marijuana dependence. Addiction. 2002;97(suppl 1):125–134. PubMed CrossRef
106. Stephens RS, Babor TF, Kadden R, et al; Marijuana Treatment Project Research Group. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction. 2002;97(suppl 1):109–124. PubMed CrossRef
107. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv. 1998;49(2):239–240. PubMed CrossRef
108. Warden D, Rush AJ, Wisniewski SR, et al. What predicts attrition in second step medication treatments for depression? a STAR*D Report. Int J Neuropsychopharmacol. 2009;12(4):459–473. PubMed CrossRef
109. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–142. PubMed CrossRef
110. Warden D, Rush AJ, Wisniewski SR, et al. Income and attrition in the treatment of depression: a STAR*D report. Depress Anxiety. 2009;26(7):622–633. PubMed CrossRef
111. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164(8):1189–1197. PubMed CrossRef
112. Watkins KE, Ober A, McCullough C, et al. Predictors of treatment initiation for alcohol use disorders in primary care. Drug Alcohol Depend. 2018;191:56–62. PubMed CrossRef
113. Watkins KE, Ober AJ, Lamp K, et al. Collaborative care for opioid and alcohol use disorders in primary care: The SUMMIT randomized clinical trial. JAMA Intern Med. 2017;177(10):1480–1488. PubMed CrossRef
114. Weinstock J, Alessi SM, Petry NM. Regardless of psychiatric severity the addition of contingency management to standard treatment improves retention and drug use outcomes. Drug Alcohol Depend. 2007;87(2-3):288–296. PubMed CrossRef
115. Petry NM, Tedford J, Austin M, et al. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction. 2004;99(3):349–360. PubMed CrossRef
116. Weisman de Mamani A, Weintraub MJ, Gurak K, et al. A randomized clinical trial to test the efficacy of a family-focused, culturally informed therapy for schizophrenia. J Fam Psychol. 2014;28(6):800–810. PubMed CrossRef
117. Ziedonis DM, Amass L, Steinberg M, et al. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend. 2009;99(1-3):28–36. PubMed CrossRef
118. Ling W, Amass L, Shoptaw S, et al; Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100(8):1090–1100. PubMed CrossRef
119. Zoellner LA, Feeny NC, Fitzgibbons LA, et al. Response of African American and Caucasian women to cognitive behavioral therapy for PTSD. Behav Ther. 1999;30(4):581–595. CrossRef
120. Nich C, Carroll KM. Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug Alcohol Depend. 2002;68(2):121–130. PubMed CrossRef
121. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. J Clin Epidemiol. 2005;58(1):13–19. PubMed CrossRef
122. Patel SG, Firmender WM, Snowden LR. Qualitative evaluation of mental health services for clients with limited English proficiency. Int J Ment Health Syst. 2013;7(1):27. PubMed CrossRef
123. Sue S, Fujino DC, Hu LT, et al. Community mental health services for ethnic minority groups: a test of the cultural responsiveness hypothesis. J Consult Clin Psychol. 1991;59(4):533–540. PubMed CrossRef
124. Kumpfer KL, Alvarado R, Smith P, et al. Cultural sensitivity and adaptation in family-based prevention interventions. Prev Sci. 2002;3(3):241–246. PubMed CrossRef
125. Cook BL, McGuire TG, Zaslavsky AM. Measuring racial/ethnic disparities in health care: methods and practical issues. Health Serv Res. 2012;47(3 Pt 2):1232–1254. PubMed CrossRef
126. Hairston DR, Gibbs TA, Wong SS, et al. Clinician bias in diagnosis and treatment. In: Medlock MM, Shtasel D, Trinh N-HT, et al, eds. Racism and Psychiatry, Chapter 7. Cham: Humana Press; 2019:105–137.
127. Radey M, Brewster KL. The influence of race/ethnicity on disadvantaged mothers’ child care arrangements. Early Child Res Q. 2007;22(3):379–393. CrossRef
128. Atdjian S, Vega WA. Disparities in mental health treatment in US racial and ethnic minority groups: implications for psychiatrists. Psychiatr Serv. 2005;56(12):1600–1602. PubMed CrossRef
129. van Ryn M, Burke J. The effect of patient race and socio-economic status on physicians’ perceptions of patients. Soc Sci Med. 2000;50(6):813–828. PubMed CrossRef
130. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17(9):643–653. PubMed CrossRef
131. Vilsaint CL, NeMoyer A, Fillbrunn M, et al. Racial/ethnic differences in 12-month prevalence and persistence of mood, anxiety, and substance use disorders: variation by nativity and socioeconomic status. Compr Psychiatry. 2019;89:52–60. PubMed CrossRef
132. Souery D, Oswald P, Massat I, et al; Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070. PubMed CrossRef
133. Teague S, Youssef GJ, Macdonald JA, et al; SEED Lifecourse Sciences Theme. Retention strategies in longitudinal cohort studies: a systematic review and meta-analysis. BMC Med Res Methodol. 2018;18(1):151. PubMed CrossRef
134. Ejiogu N, Norbeck JH, Mason MA, et al. Recruitment and retention strategies for minority or poor clinical research participants: lessons from the Healthy Aging in Neighborhoods of Diversity across the Life Span study. Gerontologist. 2011;51(suppl 1):S33–S45. PubMed CrossRef
135. Hicks S, Duran B, Wallerstein N, et al. Evaluating community-based participatory research to improve community-partnered science and community health. Prog Community Health Partnersh. 2012;6(3):289–299. PubMed CrossRef
136. Wells KB, Jones L, Chung B, et al. Community-partnered cluster-randomized comparative effectiveness trial of community engagement and planning or resources for services to address depression disparities. J Gen Intern Med. 2013;28(10):1268–1278. PubMed CrossRef
137. Zestcott CA, Blair IV, Stone J. Examining the presence, consequences, and reduction of implicit bias in health care: a narrative review. Group Process Intergroup Relat. 2016;19(4):528–542. PubMed CrossRef
138. Aggarwal NK, Chen D, Lam P, et al. Implementing the cultural formulation interview in a community clinic to improve appointment retention: a pilot study. Psychiatr Serv. 2022;73(2):227–230. PubMed CrossRef
139. Bonevski B, Randell M, Paul C, et al. Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups. BMC Med Res Methodol. 2014;14(1):42. PubMed CrossRef
140. Lewis-Fernández R, Balán IC, Patel SR, et al. Impact of motivational pharmacotherapy on treatment retention among depressed Latinos. Psychiatry. 2013;76(3):210–222. PubMed CrossRef
141. Schraufnagel TJ, Wagner AW, Miranda J, et al. Treating minority patients with depression and anxiety: what does the evidence tell us? Gen Hosp Psychiatry. 2006;28(1):27–36. PubMed CrossRef
142. Crits-Christoph P, Siqueland L, Blaine J, et al. The National Institute on Drug Abuse Collaborative Cocaine Treatment Study: rationale and methods. Arch Gen Psychiatry. 1997;54(8):721–726. PubMed CrossRef